Indianapolis-based Eli Lilly just logged another big win in the metabolic medicine race, reporting that its experimental triple-agonist drug retatrutide cleared a late-stage trial in people with type 2 diabetes. The treatment delivered meaningful blood-sugar reductions and double-digit average weight loss at 40 weeks. The readout, the first TRANSCEND diabetes study to report, follows Lilly’s headline-making TRIUMPH obesity results and adds fresh fuel to the company’s push into next-generation therapies. Around Indianapolis, biotech watchers and health-care insiders say the news raises the stakes for manufacturing plans, regulatory strategy and how quickly patients might eventually get access.
Retatrutide “lowered hemoglobin A1c an average of 1.7% to 2.0% across doses at 40 weeks and produced an average weight loss of 15.3% among all randomized participants and 16.8% among completers,” according to CNBC. At the highest dose, gastrointestinal side effects were common: nausea in about 26.5% of patients, vomiting about 17.6%, and diarrhea about 22.8%. Discontinuations for side effects were reported at roughly up to 5%. The company also said it has not yet filed for approval and expects additional phase 3 readouts later this year, per the CNBC report.
What retatrutide does and prior Phase 3 results
Retatrutide is a single molecule that activates receptors for GLP-1, GIP and glucagon, a “triple” mechanism Lilly says may help explain the combined effects on weight and glucose, as detailed in a press release from Eli Lilly. That company release also reported the December TRIUMPH-4 phase 3 obesity readout showing about 28.7% average weight loss at the highest dose over 68 weeks. Those earlier phase 3 results helped set expectations for the diabetes readout.
How the diabetes numbers compare
The diabetes readout places retatrutide ahead of many currently available options on average weight-loss measures. For context, the SURPASS-2 40-week trial of tirzepatide, the active ingredient in Lilly’s Zepbound and Mounjaro, produced roughly 13.1% average weight loss at 40 weeks, according to Eli Lilly, a commonly cited benchmark. If regulators accept broader indications, the new data could intensify the market and coverage debates that already surround GLP-1 and dual-agonist therapies.
Who was studied
The TRANSCEND diabetes study evaluated adults with type 2 diabetes who entered the trial with baseline hemoglobin A1c in the roughly 7.0%–9.5% range and measured primary outcomes at 40 weeks, according to the trial registry entry on ClinicalTrials.gov. Those enrollment criteria mean the readout reflects people with inadequately controlled diabetes on lifestyle or specified background therapy rather than newly diagnosed patients.
Why Indianapolis is watching
Lilly is headquartered in Indianapolis, and the company has been rapidly expanding U.S. manufacturing capacity, including a $3.5 billion plant in Fogelsville, Pennsylvania that the company said will make injectables and devices including next-generation weight-loss medicines, underscoring the regional economic stakes, according to AP. The scale of the retatrutide program and any eventual approval would have supply-chain implications for Lilly’s operations and for states competing for manufacturing investment.
Retatrutide remains investigational and is not available outside clinical trials; regulators will evaluate the full efficacy and safety datasets before any approval, as Lilly noted in its press materials. For clinicians and patients the headline numbers are encouraging, but full peer-reviewed publications and regulatory review will be essential to understand long-term benefits and tolerability.
